Mounjaro vs Zepbound: Are They the Same Drug? Differences, Doses and Cost (2026)

Mounjaro and Zepbound both deliver tirzepatide once a week, but the Food and Drug Administration (FDA) cleared Mounjaro to improve blood-sugar control in people with type 2 diabetes and cleared Zepbound for chronic weight management in adults with obesity or overweight plus a weight-related condition. Because the labels differ, insurers, savings cards and even the dose strengths you can pick up at the pharmacy also differ. Comparing the two brands side-by-side helps you request the right prescription and avoid paying more than you have to.

• Tirzepatide is a dual GIP/GLP-1 receptor agonist that lowers A1C and reduces appetite by slowing gastric emptying and acting on brain appetite centers  (West et al., 2025).
• Mounjaro received FDA approval for type 2 diabetes in May 2022 with six single-dose pen strengths ranging from 2.5 mg to 15 mg (fda.gov).
• Zepbound was approved for weight management in November 2023 and offers the same six strengths, but its label includes 7.5 mg and 12.5 mg dose stops to slow titration (fda.gov).
• The wholesale list price is $1,079.77 per four-pen pack for Mounjaro (2.5-15 mg) (pricinginfo.lilly.com), versus $1,059.87 for Zepbound (investor.lilly.com).
• Eli Lilly savings cards let many commercially insured patients pay as little as $25 for a 1- to 3-month supply of either brand (mounjaro.lilly.com).
• In a pooled analysis of trials and real-world cohorts, tirzepatide produced about 4.23 percentage points greater weight loss than semaglutide when given at comparable doses (Aamir et al., 2025).

Are Mounjaro and Zepbound the same drug?

Yes and no: both pens contain the active ingredient tirzepatide, but the FDA treats them as separate products with distinct approved uses and National Drug Codes (NDCs). Mounjaro is labelled “adjunct to diet and exercise to improve glycemic control” in adults (and now children 10+ years) with type 2 diabetes (fda.gov). Zepbound is labelled “chronic weight management” in adults with a body-mass index (BMI) ≥ 30 kg/m², or ≥ 27 kg/m² with at least one weight-related condition (fda.gov).

Why two names? Federal law prevents a sponsor from marketing one drug for multiple, unrelated conditions until each use has been expressly reviewed. Separate trademarks also help insurers apply different coverage rules-critical because many plans still exclude anti-obesity drugs.

How tirzepatide works in diabetes vs weight loss

Tirzepatide binds both GIP and GLP-1 receptors. The dual action boosts insulin secretion, dampens glucagon and slows stomach emptying, leading to lower post-meal glucose and prolonged satiety (West et al., 2025).

Diabetes focus: Clinical trials showed Mounjaro lowered hemoglobin A1C by up to 2.3 percentage points and produced secondary weight loss. Those glucose reductions drive its diabetes indication.

Weight-loss focus: Zepbound’s phase 3 SURMOUNT-1 and −2 programs prioritized percent body-weight change. The pooled meta-analysis cited above found tirzepatide outperformed semaglutide by 4.23 percentage points on this endpoint (Aamir et al., 2025). That efficacy underpins its obesity indication.

Dose schedules and titration differences

Both brands start at 2.5 mg once weekly for 4 weeks, but the allowable step-ups diverge after that first month.

Dose form differences: Zepbound is sold in single-dose pens or multi-dose vials (2.4 mL) for specialty pharmacy programs, while Mounjaro remains single-dose only. The vial is meant to ease large-scale employer and Medicare programs launching in 2026.

Cost, insurance coverage and savings cards

Sticker price tells only half the story. Wholesale Acquisition Cost (WAC) is what wholesalers pay Lilly-not what you’ll pay at the counter.

Insurance nuances: Most major commercial plans cover Mounjaro because it treats diabetes. Fewer cover Zepbound, especially in employer plans that still exclude weight-loss drugs. Medicare will cap Zepbound out-of-pocket costs at $50 per month starting April 2026 under the GLP-1 Bridge model (investor.lilly.com).

💡 Tip for appeals

If your insurer denies Zepbound for “cosmetic weight loss,” ask your provider to list every qualifying comorbidity (sleep apnea, hypertension, fatty liver) and attach BMI and fasting glucose labs. Many plans reverse denials when additional ICD-10 codes document medical necessity.

Side-effect profile and real-world safety signals

Labels list the same class-wide gastrointestinal issues, but post-marketing data hint at dosing-error spikes as usage grows.

GI events are predictable. A 2026 nutrition review found nausea, vomiting and reflux are the top reasons patients stop incretin therapy, but meal-size modification and protein spacing can curb symptoms (Pardali et al., 2026).

What if insurance still will not cover tirzepatide?

If prior authorization fails or you lose coverage mid-treatment, a compounded version of tirzepatide, prepared by a licensed 503A pharmacy and prescribed by a licensed U.S. provider, can be an option for some adults. Compounded tirzepatide is not FDA-approved and is not the same as any brand-name medication. Through the Rx.com weight loss program, compounded tirzepatide is available from $149 per month on a 12-month plan, with the online visit and shipping included. This route bypasses insurance but still requires a valid prescription and clinical oversight.